{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:07:22Z","timestamp":1793390842388,"version":"4.5.0"},"reference-count":34,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Weight management is key to managing polycystic ovary syndrome (PCOS) and overweight\/obesity but is challenging for many. Evidence regarding tirzepatide's efficacy in women with polycystic ovary syndrome is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To quantify the effectiveness of tirzepatide for weight loss in women with (self-reported) polycystic ovary syndrome and overweight\/obesity compared with women not living with PCOS and to explore associations between engagement with nonpharmacological digital adjuncts and weight loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective open-cohort study in a digital weight management service in the United Kingdom. All women (aged 18+ years) with overweight\/obesity prescribed tirzepatide for weight management between February 2024 and January 2025 were included. Percentage weight change from baseline was calculated in women reaching specific follow-up time points, stratified by PCOS status. Kaplan-Meier methods estimated cumulative probabilities of attaining total body weight loss thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort comprised 54 114 women of whom 4241 (7.84%) women had PCOS. At 10 months, the mean weight change in women with PCOS (n = 40) was \u221219.40% (95% confidence interval [CI], \u221222.38% to \u221216.42%); this was not significantly different from women without PCOS (n = 397; mean weight change, \u221218.74%; 95% CI, \u221219.67% to \u221217.81%). A total of 57.66% of women with PCOS lost \u226520% total body weight (95% CI, 47.44% to 68.29%) by 10 months. In women living with PCOS, digitally engaged women lost 3.42% more weight in absolute terms (95% CI, 1.71% to 5.12%; P &amp;lt; .001) by 10 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tirzepatide may offer a highly effective therapeutic option for women with PCOS and overweight\/obesity in whom weight loss is a key goal but a persistent challenge.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvag177","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:18:27Z","timestamp":1786965507000},"source":"Crossref","is-referenced-by-count":2,"title":["Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome"],"prefix":"10.1210","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0061-979X","authenticated-orcid":false,"given":"Ashley Kieran","family":"Clift","sequence":"first","affiliation":[{"name":"Department of Clinical Research, Voy (Menwell Ltd) , London SE1 9HZ ,","place":["UK"]},{"name":"Department of Surgery & Cancer, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Reisel","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Voy (Menwell Ltd) , London SE1 9HZ ,","place":["UK"]},{"name":"EGA Institute for Women's Health, University College London , London WC1E 6DE ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Voy (Menwell Ltd) , London SE1 9HZ ,","place":["UK"]},{"name":"Department of Digital Health and Care, University of Bristol , Bristol BS1 5DD ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":false,"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"BHF Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TD ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Voy (Menwell Ltd) , London SE1 9HZ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"9","key":"2026082322065834600_bvag177-B1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S2213-8587(22)00163-2","article-title":"Polycystic ovary syndrome","volume":"10","author":"Joham","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026082322065834600_bvag177-B2","doi-asserted-by":"crossref","DOI":"10.1530\/EC-24-0529","article-title":"Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review","volume":"14","author":"Monney","year":"2025","journal-title":"Endocr Connect"},{"issue":"1","key":"2026082322065834600_bvag177-B3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-024-00511-3","article-title":"Polycystic ovary syndrome","volume":"10","author":"Stener-Victorin","year":"2024","journal-title":"Nat Rev Dis Primer"},{"issue":"4","key":"2026082322065834600_bvag177-B4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2023.07.025","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"120","author":"Teede","year":"2023","journal-title":"Fertil Steril"},{"issue":"6","key":"2026082322065834600_bvag177-B5","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.fertnstert.2008.09.018","article-title":"Treatment of obesity in polycystic ovary syndrome: a position statement of the androgen excess and polycystic ovary syndrome society","volume":"92","author":"Moran","year":"2009","journal-title":"Fertil Steril"},{"key":"2026082322065834600_bvag177-B6","volume-title":"Polycystic Ovary Syndrome","author":"WHO","year":"2025"},{"issue":"1","key":"2026082322065834600_bvag177-B7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12958-024-01339-y","article-title":"Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review","volume":"23","author":"Duah","year":"2025","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"2026082322065834600_bvag177-B8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s13679-025-00614-2","article-title":"Weight management strategies to reduce metabolic morbidity in women with polycystic ovary syndrome","volume":"14","author":"Diakosavvas","year":"2025","journal-title":"Curr Obes Rep"},{"issue":"1","key":"2026082322065834600_bvag177-B9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12905-025-03594-6","article-title":"Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a network meta-analysis of randomized controlled trials","volume":"25","author":"Bo","year":"2025","journal-title":"BMC Womens Health"},{"issue":"4","key":"2026082322065834600_bvag177-B10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/GCO.0000000000001028","article-title":"The use of GLP-1: receptor agonist medications for benign gynecology","volume":"37","author":"Howard","year":"2025","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"1","key":"2026082322065834600_bvag177-B11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"2026082322065834600_bvag177-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms26010001","article-title":"Adropin\/tirzepatide combination mitigates cardiac metabolic aberrations in a rat model of polycystic ovarian syndrome, implicating the role of the AKT\/GSK3\u03b2\/NF-\u03baB\/NLRP3 pathway","volume":"26","author":"Hegab","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026082322065834600_bvag177-B13","first-page":"4","article-title":"Impact of dramatic weight loss with the new injectable medications on reproduction in healthy non-polycystic ovary syndrome obese women","volume":"6","author":"Merhi","year":"2025","journal-title":"F S Rep"},{"issue":"14","key":"2026082322065834600_bvag177-B14","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.3390\/jcm12144575","article-title":"The potential utility of tirzepatide for the management of polycystic ovary syndrome","volume":"12","author":"Anala","year":"2023","journal-title":"J Clin Med"},{"issue":"5","key":"2026082322065834600_bvag177-B15","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13704","article-title":"Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline","volume":"25","author":"Goldberg","year":"2024","journal-title":"Obes Rev"},{"key":"2026082322065834600_bvag177-B16"},{"issue":"6","key":"2026082322065834600_bvag177-B17","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","article-title":"Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review","volume":"39","author":"Jensterle","year":"2022","journal-title":"Adv Ther"},{"key":"2026082322065834600_bvag177-B18","doi-asserted-by":"crossref","DOI":"10.2196\/69466","article-title":"Impact of digital engagement on weight loss outcomes in obesity management among individuals using GLP-1 and dual GLP-1\/GIP receptor agonist therapy: retrospective cohort service evaluation study","volume":"27","author":"Johnson","year":"2025","journal-title":"J Med Internet Res"},{"issue":"1","key":"2026082322065834600_bvag177-B19","doi-asserted-by":"crossref","DOI":"10.1002\/osp4.70036","article-title":"Long-term weight loss outcomes in a virtual weight care clinic prescribing a broad range of medications alongside behavior change","volume":"11","author":"Clark","year":"2025","journal-title":"Obes Sci Pract"},{"issue":"7624","key":"2026082322065834600_bvag177-B20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"2026082322065834600_bvag177-B21","doi-asserted-by":"crossref","unstructured":"Clift AK, Reisel D, Johnson H, et al \u00a0Supplementary figures for manuscript: Weight loss outcomes with tirzepatide in women with and without polycystic ovary syndrome. Zenodo; 2026. 10.5281\/zenodo.19006589","DOI":"10.1210\/jendso\/bvag177"},{"issue":"8","key":"2026082322065834600_bvag177-B22","article-title":"Clinical effects of glucagon-like peptide-1 agonist use for weight loss in women with polycystic ovary syndrome: a scoping review","volume":"16","author":"Frangie Machado","year":"2024","journal-title":"Cureus"},{"issue":"11","key":"2026082322065834600_bvag177-B23","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/oby.24138","article-title":"Coach access to digital self-monitoring data: an experimental test of short-term effects in behavioral weight-loss treatment","volume":"32","author":"Butryn","year":"2024","journal-title":"Obesity (Silver Spring, Md.)"},{"issue":"3","key":"2026082322065834600_bvag177-B24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s13679-023-00515-2","article-title":"The effectiveness of eHealth interventions for weight loss and weight loss maintenance in adults with overweight or obesity: a systematic review of systematic reviews","volume":"12","author":"Kupila","year":"2023","journal-title":"Curr Obes Rep"},{"issue":"4","key":"2026082322065834600_bvag177-B25","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2023.08.635","article-title":"Effects of metformin alone versus metformin and tirzepatide on weight loss in patients with polycystic ovarian syndrome (PCOS)","volume":"120","author":"Sassin","year":"2023","journal-title":"Fertil Steril"},{"issue":"10","key":"2026082322065834600_bvag177-B26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108834","article-title":"The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials","volume":"38","author":"Austreg\u00e9silo de Athayde De Hollanda Morais","year":"2024","journal-title":"J Diabetes Complications"},{"issue":"4","key":"2026082322065834600_bvag177-B27","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/dom.70452","article-title":"Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: a systemati review and meta-analysis","volume":"28","author":"Lu","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"2026082322065834600_bvag177-B28","author":"Sutton"},{"key":"2026082322065834600_bvag177-B29","author":"NHS Digital"},{"issue":"6","key":"2026082322065834600_bvag177-B30","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1210\/clinem\/dgae705","article-title":"Polycystic ovary syndrome underdiagnosis patterns by individual-level and spatial social vulnerability measures","volume":"110","author":"Silva","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026082322065834600_bvag177-B31","doi-asserted-by":"crossref","first-page":"e1759","DOI":"10.1210\/clinem\/dgaf037","article-title":"Population-based vs health system and insurer records: significant underdiagnosis of PCOS","volume":"110","author":"Hatoum","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026082322065834600_bvag177-B32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12905-023-02394-0","article-title":"Factors associated with self-report of polycystic ovary syndrome in the coronary artery risk development in young adults study (CARDIA)","volume":"23","author":"Kim","year":"2023","journal-title":"BMC Womens Health"},{"key":"2026082322065834600_bvag177-B33","article-title":"Polycystic ovary syndrome: why widening the diagnostic criteria may be harming women","volume":"373","author":"Copp","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"2026082322065834600_bvag177-B34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/humrep\/15.1.24","article-title":"Women with polycystic ovary syndrome gain regular menstrual cycles when ageing","volume":"15","author":"Elting","year":"2000","journal-title":"Human reproduction (Oxford, England)"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvag177\/70689480\/bvag177.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/9\/bvag177\/70689480\/bvag177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/9\/bvag177\/70689480\/bvag177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:07:08Z","timestamp":1787537228000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvag177\/8764203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvag177","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,1]]},"article-number":"bvag177"}}